baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC BON.CAP.CERT. 12/24 PFE/ DE000HD3TXM8 /

2024-06-10 9:45:26 AM	Chg.-0.030	Bid10:30:27 AM	Ask10:30:27 AM	Underlying	Strike price	Expiration date	Option type
33.020EUR	-0.09%	32.990 Bid Size: 1,000	33.030 Ask Size: 1,000	Pfizer Inc	- USD	2024-12-31	Call

GlobeNewswire 06-05 Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Co...

GlobeNewswire 06-03 Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases

GlobeNewswire 05-16 Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combinatio...

TeleTrader 05-01 Pfizer's Q1 revenue drops 20% to $14.9 billion

GlobeNewswire 04-30 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...

GlobeNewswire 03-22 Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous ...

GlobeNewswire 03-20 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

GlobeNewswire 03-07 BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...

GlobeNewswire 03-07 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...

GlobeNewswire 03-05 LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd...

GlobeNewswire 02-28 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...

GlobeNewswire 02-28 BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...

GlobeNewswire 02-27 Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment t...

GlobeNewswire 02-23 Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market

GlobeNewswire 02-20 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...

GlobeNewswire 02-16 ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Befo...

GlobeNewswire 02-11 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...

GlobeNewswire 02-08 ROSEN, A RANKED AND LEADING FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Importan...

GlobeNewswire 02-06 Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment o...

GlobeNewswire 02-03 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...

TeleTrader 01-30 Pfizer posts Q4 revenue of $14B, reaffirms guidance

GlobeNewswire 01-26 ROSEN, A LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadl...

GlobeNewswire 01-26 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...

GlobeNewswire 01-18 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...

GlobeNewswire 2023-12-21 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...

UC BON.CAP.CERT. 12/24 PFE/ DE000HD3TXM8 /

If you wish to receive reply to your feedback, please provide your email address.